Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer
NCT00494338
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
6
Enrollment
INDUSTRY
Sponsor class
Stopped
due to celecoxib safety issues
Conditions
Metastatic Prostate Cancer
Interventions
DRUG:
Docetaxel
Sponsor
Sanofi